Sinopharm (Beijing): BBIBP-CorV (Vero Cells)
Vaccine Type: Inactivated
This vaccine may also be referred to as Covilo
Vaccine Trial & Approval Tracker
This vaccine is approved.
Phase 1: 1 Trial
-
ChiCTR2000032459
China
Phase 2: 2 Trials
-
ChiCTR2000032459
China -
NCT04998240
Mozambique
Phase 3: 8 Trials
-
IRCT20210206050259N3
Iran (Islamic Republic of) -
IRCT20201214049709N3
Iran (Islamic Republic of) -
ChiCTR2000034780
United Arab Emirates -
NCT04612972
Peru -
NCT04510207
Bahrain, Egypt, Jordan, United Arab Emirates -
NCT04560881, BIBP2020003AR
Argentina -
NCT04917523
United Arab Emirates -
NCT04984408
Approvals
64 Countries
- Angola
- Argentina
- Bahrain
- Bangladesh
- Belarus
- Belize
- Bolivia (Plurinational State of)
- Brazil
- Brunei Darussalam
- Cambodia
- Cameroon
- Chad
- China
- Comoros
- Cuba
- Egypt
- Equatorial Guinea
- Gabon
- Gambia
- Georgia
- Guyana
- Hungary
- Indonesia
- Iran (Islamic Republic of)
- Iraq
- Jordan
- Kenya
- Kyrgyzstan
- Lao People's Democratic Republic
- Lebanon
- Malaysia
- Maldives
- Mauritania
- Mauritius
- Mexico
- Mongolia
- Montenegro
- Morocco
- Mozambique
- Namibia
- Nepal
- Niger
- Nigeria
- North Macedonia
- Pakistan
- Paraguay
- Peru
- Philippines
- Republic of the Congo
- Senegal
- Serbia
- Seychelles
- Sierra Leone
- Solomon Islands
- Somalia
- Sri Lanka
- Thailand
- Trinidad and Tobago
- Tunisia
- United Arab Emirates
- Vanuatu
- Venezuela (Bolivarian Republic of)
- Viet Nam
- Zimbabwe
This vaccine is also manufactured by G42 Healthcare (Hayat-Vax)
Registered Trials
-
IRCT20210206050259N3
Phase 3Iran (Islamic Republic of)
Total Enrollment: 41,128
Official Trial Registration:
-
IRCT20201214049709N3
Phase 3Iran (Islamic Republic of)
Total Enrollment: 41,128
Official Trial Registration:
-
ChiCTR2000034780
Phase 3United Arab Emirates
Total Enrollment: 45,000
Official Trial Registration:
-
NCT04612972
Phase 3Peru
Total Enrollment: 6,000
Official Trial Registration:
-
NCT04510207
Phase 3Bahrain, Egypt, Jordan, United Arab Emirates
Total Enrollment: 45,000
Official Trial Registration:
-
NCT04560881, BIBP2020003AR
Phase 3Argentina
Total Enrollment: 3,000
Official Trial Registration:
-
NCT04917523
Phase 3United Arab Emirates
Total Enrollment: 1,800
Official Trial Registration:
-
NCT04984408
Phase 3Total Enrollment: 8,825
Official Trial Registration:
-
NCT04998240
Phase 2Mozambique
Total Enrollment: 360
Official Trial Registration:
-
ChiCTR2000032459
Phase 1/2China
Total Enrollment: 640
Official Trial Registration: